A phase I study of ICT03-Es5 for the treatment of solid tumors.
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2016
At a glance
- Drugs ICT03 Es5 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 28 Jul 2016 New trial record
- 23 Jul 2016 According to a Incanthera media release, the company plans to initiate the trial in 2017.